AGIBOT Laparoscopic Surgical Robot Completes Clinical Trial in Gynecology in PLA General Hospital

On October 23, 2024, Professor Meng Yuanguang successfully performed the final procedure of a robotic-assisted malignant endometrial tumor resection in the operating room of the First Medical Center at the Chinese People’s Liberation Army (PLA) General Hospital. This marks the successful conclusion of the clinical trial of the AGIBOT laparoscopic surgical robot, independently developed by AGIBOT Medical Technology (Suzhou) Co., Ltd. (AGIBOT), in the gynecology department at PLA General Hospital. This milestone also signifies a key advancement in AGIBOT’s multicenter, multi-specialty clinical trials.

The multi-specialty clinical trial for AGIBOT Laparoscopic Surgical Robot was led by Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, in collaboration with the First Affiliated Hospital of Zhengzhou University and PLA General Hospital. The trial involved multiple surgical specialties, including general surgery (encompassing hepatobiliary surgery, gastrointestinal surgery, and colorectal surgery procedures), thoracic surgery, and gynecology. A series of medium- to high-complexity surgical procedures were performed to rigorously evaluate the efficacy and safety of AGIBOT Laparoscopic Surgical Robot in real-world clinical applications, aiming to establish it as a reliable, innovative solution for both surgeons and patients.

Under the leadership of Prof. Meng Yuanguang, Director of the Department of Obstetrics and Gynecology at PLA General Hospital, and with the support of Professor Li Li’an, the gynecology clinical trial progressed smoothly, with successful completion of 10 complex surgical procedures. These included radical hysterectomy for cervical cancer and comprehensive staging for endometrial cancer, achieving a 100% procedural success rate. Intraoperative metrics and postoperative outcomes demonstrated excellent surgical precision and favorable patient recovery. Several cases required advanced techniques such as pelvic and para-aortic lymph node dissection, which posed significant technical challenges and placed high demands on the robot’s performance. AGIBOT laparoscopic surgical robot excelled in these scenarios, receiving high praise from the surgical team for its stability, precision, and reliability.

Prof. Meng Yuanguang remarked:“The AGIBOT Laparoscopic Surgical Robot has demonstrated outstanding performance in complex gynecological surgeries. Particularly in the treatment of cervical and endometrial cancers, its stable platform and precise instrument control enabled us to complete intricate pelvic dissections and lymphadenectomy with greater ease. This not only enhanced surgical accuracy but also contributed positively to patient outcomes and recovery.”

Landmark Achievement: On September 9, 2024, Prof. Li Li’an achieved a milestone with the 100th successful procedure using AGIBOT Laparoscopic Surgical Robot, completing comprehensive staging surgery for endometrial cancer at PLA General Hospital.

Prior to the introduction of AGIBOT Laparoscopic Surgical Robot into clinical practice, Prof. Li Li’an, under the direction of Prof. Meng Yuanguang, led a team to conduct preliminary testing and inspection of the robot at AGIBOT, Suzhou. Collaborating closely with AGIBOT’s product and medical teams, they performed animal trials to familiarize themselves with the robot’s operation while conducting an initial evaluation of its safety and effectiveness. Subsequently, before clinical deployment, medical team of AGIBOT provided comprehensive on-site training for all participating medical personnel at PLA General Hospital, ensuring a thorough understanding of the functionality and capabilities to support the successful execution of the clinical trial.

During the clinical trial, the gynecology team at PLA General Hospital provided valuable feedback and recommendations for optimizing the AGIBOT Laparoscopic Surgical Robot, reflecting their rigorous standards and high expectations for product performance and clinical outcomes. AGIBOT will integrate these insights to drive continuous improvements, translating expert input into more reliable and efficient surgical solutions. 

The successful completion of the gynecology clinical trial at PLA General Hospital highlights the active participation and robust support of China’s leading medical institutions in advancing the development and clinical application of domestically produced surgical robotic systems. This achievement marks a significant step forward in the innovation and practical adoption of Chinese endoscopic robotic technology. AGIBOT remains committed to collaborating with clinical institutions to promote the accessibility and widespread adoption of robotic-assisted endoscopic surgery, benefiting patients and medical professionals alike.